Introduction
It is well established that a family history of breast cancer is associated with an increased risk of developing breast cancer. In fact, among those variables that have been shown to bear a relationship with breast cancer, the highest risk, after age, is the presence of a positive family history of breast cancer [1] .
Among breast cancer patients, up to 5-10% are considered directly related to the inheritance of mutations in BRCA1 or BRCA2 genes [2] , which accounts for most hereditary breast cancers. Claus et al. [2] estimated the proportion of breast cancer attributable to inherited autosomal dominant genes to be approximately 33% in subjects aged 20-29 years. This estimated risk decreased with age at onset to approximately 1.5% of case subjects aged 70 years or more. Women carrying these mutations have a lifetime risk of breast cancer of 60-80% [3] ; therefore, detection of mutations in these two genes can be used as a molecular predictor for breast cancer.
At present, data suggest that a mutation in BRCA1 accounts for the majority (80-90%) of families containing multiple case subjects with breast and/or ovarian cancer, and approximately 45% of inherited breast cancers [4] , whereas a mutation in BRCA2 is thought to account for approximately 35% of inherited breast cancers [3] .
Genetic screening
As a consequence of current trends in multidisciplinary therapy for breast cancer, BRCA1 and BRCA2 genes are not only useful as molecular markers for hereditary breast cancer risk screening, but have also become important indicators for prevention, treatment, and prognosis of breast cancer.
Screening for BRCA1 or BRCA2 mutations is difficult. In a large proportion of patients with breast cancer who have a family history strongly pointing to hereditary disease, a BRCA1 or BRCA2 mutation cannot be demonstrated. This may be partly explained by germline mutations in less common genes other than BRCA1 or BRCA2, such as in the TP53 gene, which is associated with Li-Fraumeni syndrome; in the PTEN gene, which is associated with Cowden syndrome; in the CHEK2 gene; or in the ataxia telangiectasia mutated gene [5] . Mutations in BRCA1 or BRCA2 may be missed in current screening procedures, even with complete sequencing [6] . It is currently possible to detect about 90% of all BRCA1 or BRCA2 mutations by using standard diagnostic procedures, and a mutation is detected in almost 25% of cases presenting with familial cancer.
Not all women are candidates for genetic testing. In order to maximize both the efficiency of testing and the public health impact of a genetic screening program, many centers offer screening to women when the prior probability of finding a mutation is 10% or greater [7] . Several mathematical models such as BRCAPRO (http://astor. som.jhmi.edu/BayesMendel/brcapro.html) and the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) can be used to estimate the prior probability of carrying a mutation [8, 9] . These models consider age of onset and family history of cancer.
Although the decision to offer genetic testing to a breast cancer patient is usually based on family history, if the family history is not available, some women may qualify for testing based on age of onset or the breast tumor's pathologic features.
Certain tumor characteristics can also be used to predict the presence of a mutation. BRCA1-associated cancers are typically of high grade and ''triple negative'' (i.e. negative for estrogen receptors [ER], progesterone receptors [PR] and human epidermal growth factor receptor-2 [HER2] expression) [10] . The majority of triple negative cancers (80 to 90%) also exhibit a basal phenotype (expression of cytokeratins and HER2). The proportion of basal phenotype BRCA1-associated cancers has been estimated at 88% [10] .
The proportion of BRCA1-associated cancers that are ER-negative diminishes with increasing age of onset. Foulkes et al. [11] found that 81% of BRCA1-associated breast cancers diagnosed before age 45 were ER-negative, compared to 62% of breast cancers diagnosed after age 65.
Genetic syndromes that carry a significant risk of breast cancer are responsible for a small but significant percentage of these cancers. However, the vast majority of breast tumors occurs in women with no family history of the disease. Non-genetic risk factors include age, previous breast disease, breast tissue density, radiation exposure, and lifestyle factors such as weight, exercise, and alcohol consumption [12] .
When a woman under the age of 40 years develops breast cancer, a hereditary predisposition may be suspected whether there is a family history or not. If there is a family history of two or more family members under 50 years of age with breast cancer, male breast cancer, or ovarian cancer, or a Li-Fraumeni or Cowden syndrome is suspected, the likelihood of a genetic predisposition is high. If there is no family history, the suspicion that the breast cancer is due to a heritable genetic mutation is based on tumor bilaterality, tumor phenotype (triple negative and basal phenotypes), and a simultaneous diagnosis of ovarian cancer. It is also important to discard a possible paternal transmission due to little information regarding inheritance patterns.
Studies comparing survival between BRCA1-and BRCA2-associated and sporadic breast cancers have inconsistent results. The prognosis of the disease depends on whether the mutation has occurred in the BRCA1 or BRCA2 gene. If a mutation has occurred in BRCA1, some studies have attributed a similar prognosis when compared with sporadic breast cancer patients [13] , while other studies have attributed a worse prognosis [14] . In BRCA2 mutation carriers, the prognosis may also be better [15] or similar when compared with age-matched sporadic breast cancer patients [16] .
Genetic counseling and management of women with hereditary breast cancer
A young woman with breast cancer will probably express her concern about whether her tumor is inherited because of the possibility of transmitting it to her offspring. The patient will also be concerned about whether there will be additional risks throughout her life to develop other mutations or, if by virtue of being inherited, she has a worse prognosis. Furthermore, knowing if breast cancer is inherited is important in deciding the treatment of advanced disease.
The discovery of BRCA1 and BRCA2 mutations has raised a number of questions regarding the optimal management of women with hereditary breast carcinoma. The appropriateness of breast-conserving therapy for women with hereditary breast carcinoma is an area of ongoing discussion. Women with BRCA-associated breast carcinoma who undergo breast-conserving surgery appear to have a risk of metachronous ipsilateral breast carcinoma similar to that reported for young women without known mutations [17] . The indications for unilateral mastectomy in this group of women should, therefore, be the same as for women with nonhereditary carcinoma. However, a significant risk of contralateral breast carcinoma and possibly late metachronous ipsilateral breast carcinoma may prompt consideration of bilateral mastectomy as a preventive measure [17] . A study by GarciaEtienne et al. [18] showed that the risk of ipsilateral breast tumor recurrence after breast-conserving surgery in BRCA1/2 mutation carriers was increased compared with patients who had sporadic breast cancer. Likewise, the risk of contralateral breast cancer seemed to be increased in this group.
Neoadjuvant chemotherapy for breast cancer is often given prior to surgery to decrease the size of the tumor so that breast-conserving surgery can be performed, and to reduce the probability of lymph node involvement. Patients with BRCA1/2 mutations show a better clinical response rate to neoadjuvant chemotherapy than patients without mutations in the BRCA gene.
The use of platinum-based neoadjuvant chemotherapy has been effective in a high proportion of patients with BRCA1-associated breast cancers [19] . Another study reported that BCRA1/2 carriers showed a better clinical response rate to neoadjuvant treatment than non-carriers [20] . There is also a study that has demonstrated the therapeutic efficacy of treatment in advanced breast cancer. In a phase II trial, the efficacy of the oral poly (ADPribose) polymerase inhibitor olaparib in BRCA-deficient advanced breast cancer was evidenced [21] .
BRCA1/2 genes are transmitted in an autosomal dominant pattern. Because this can influence an individual's decision regarding reproduction, health care professionals should ensure patient education regarding the potential impact of BRCA inheritance on family planning. Preimplantation genetic diagnosis in women carrying BRCA mutations has been approved in some countries. Women at increased risk for hereditary cancer may consider this procedure as part of their reproductive decision making. Therefore, it is important to understand existing levels of awareness and attitudes toward this technology to provide optimal counseling and support [22] .
Conclusions
The identification of a possible hereditary predisposition to breast cancer is important because the prevalence of familial breast cancer is sufficiently high to have a clinical impact. Importantly, genetic screening must be done at the time of diagnosis, not when adjuvant chemotherapy is being administered as has been done so far. This is because information regarding BRCA1/2 mutation status is important for the young patient with breast cancer in order to undertake opportune prophylactic measures, such as bilateral mastectomy, evaluate consequences on reproduction, make timely treatment decisions in case a breast tumor develops, and provide adequate genetic counseling to the patient and family members. Hospitals that do not have access to Genetic Counseling Units should have contact with a referral center.
